Obstructive Sleep Apnea: The Cardiovascular Consequences of Disordered Breathing

Obstructive Sleep Apnea: The Cardiovascular Consequences of Disordered Breathing

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

---

In Brief: Obstructive sleep apnea is filed as a sleep disorder, but its most serious damage is cardiovascular — and most people who have it cannot feel it happening. During sleep the throat repeatedly collapses, and each event delivers a drop in oxygen, a surge of sympathetic activity, and a spike in blood pressure, dozens of times an hour in moderate-to-severe disease. Over years this drives hypertension, atrial fibrillation, coronary disease, heart failure, and stroke — which is why OSA turns up, usually undiagnosed, in the majority of patients with resistant hypertension and many with atrial fibrillation or heart failure. Treatment reliably improves blood pressure and symptoms, though randomized trials have not yet shown that it lowers hard cardiovascular events at the adherence levels studied. This article covers what happens during an apnea, how it injures the cardiovascular system, which conditions warrant evaluation, and what the trials do and do not show.

A Sleep Disorder That Is Really a Cardiovascular One

Articles 1 and 2 made the case that sleep is a nightly cardiovascular exposure — that what happens overnight, repeated for years, shows up later as hypertension, coronary disease, and stroke. Obstructive sleep apnea is the sharpest example of that principle, and it begins the series’ tour through the specific sleep disorders.

In obstructive sleep apnea the upper airway repeatedly collapses during sleep, so breathing stops (apnea) or is severely reduced (hypopnea). Each event triggers a fall in oxygen, mounting effort to breathe against a closed airway, and a brief arousal that reopens it. In moderate-to-severe disease the cycle repeats dozens of times an hour, all night.

It is the cardiovascular consequences that matter most. The repeated oxygen swings, the extreme pressure generated by breathing against a closed airway, the sympathetic surges that accompany each arousal, and the fragmentation of sleep do not merely cause daytime sleepiness. They raise blood pressure, promote arrhythmias, accelerate atherosclerosis, and strain the failing heart.

The prevalence in cardiovascular populations is striking. OSA is present in the majority of patients with resistant hypertension, in a large share of those undergoing coronary bypass surgery, and in many with heart failure or atrial fibrillation.(1, 16, 21, 22, 26, 45, 46) Most were never evaluated for it. They presented with cardiovascular disease, not a sleep complaint — which is the heart of the problem. The disease is largely invisible to the person who has it. The events happen below conscious awareness, the only reliable witness is a bed partner, and the symptoms that do surface — fatigue, unrefreshing sleep, trouble concentrating — get attributed to age or stress.

What Happens During an Obstructive Apnea

The Anatomy

The upper airway is not a rigid tube. The segment between the hard palate and the larynx — the pharynx — is surrounded by soft tissue: the tongue, the soft palate, and the pharyngeal walls. During wakefulness, active muscle tone holds it open. During sleep, that tone falls.(2)

In people with OSA the airway becomes collapsible enough during sleep to narrow sharply (hypopnea) or close entirely (apnea). The obstruction is “obstructive” because respiratory drive continues — the chest and diaphragm keep trying to breathe, pulling against a closed airway. That is the dividing line from central sleep apnea, where the brain briefly stops sending the signal to breathe, covered in Article 4.(2)

The Physiology of a Single Event

Understanding the cardiovascular fallout means following one apnea from start to finish.(3) The pharynx collapses and airflow stops despite continued effort. The diaphragm and chest wall pull harder against the blockage, generating increasingly negative pressure in the chest — normal inspiration runs about −5 to −10 cm H₂O, while obstructed inspiration can reach −60 to −80 cm H₂O or more.(9) With no airflow, blood oxygen falls; in mild events it dips a few points, but in severe events saturation can fall into the 70s or 60s, levels that would set off alarms in a monitored ward.

The cardiovascular system absorbs the strain in real time. Heart rate changes, blood vessels constrict, and the extreme negative chest pressure raises the load the left ventricle must pump against while pulling venous blood into the thorax and distending the right heart.(10, 11) After ten to sixty seconds, sometimes longer, the brain registers the distress and triggers a brief arousal — just enough to restore airway tone and reopen it. That arousal comes with a surge of sympathetic activity: heart rate jumps, and blood pressure rises sharply, with systolic pressures above 200 mmHg documented in severe events.(14) The reoxygenation itself generates oxidative stress. The arousal is usually too short to reach awareness, so the person drifts back to sleep, tone falls, the airway collapses, and the cycle repeats. In severe OSA — an apnea-hypopnea index of 30 or more — this can happen over thirty times an hour, hundreds of times a night.

To see the scale, picture one stretch of a severe night.

Time	What happens
11:00 PM	Sleep begins
11:02 PM	The airway collapses; effort continues against the blockage
11:03 PM	Oxygen falls; heart rate and blood pressure surge
11:03 PM	A brief arousal reopens the airway
11:04 PM	Sleep resumes; muscle tone falls again
11:05 PM	The airway collapses again — and the cycle restarts
All night	The same loop, over and over

An apnea-hypopnea index of 60 — not unusual in severe disease — means roughly one event every minute, all night long. That is the scale of the exposure the cardiovascular system is absorbing.

What the Person Experiences

Most people with OSA do not know their breathing is stopping, because the arousals are too brief to remember. What they notice instead is nonspecific: unrefreshing sleep despite enough time in bed, morning headaches that fade within a few hours, daytime fatigue and trouble concentrating, and waking repeatedly to urinate. The morning headaches are thought to stem from the overnight swings in oxygen and carbon dioxide and from fragmented sleep. Bed partners usually notice more — loud snoring, gasping, and the silent pauses that end in a snort.

The gap between how severe the disease is and how little the person feels is the central problem. Someone can have hundreds of events a night, with oxygen dipping into the 70s and real cardiovascular stress each time, and report only that they are “a little tired.” The exposure accumulates while everyone, including the patient, looks elsewhere.

Why It Often Goes Undiagnosed

Several factors line up to keep OSA hidden, which is why it is so often found late or by accident. Chief among them is that patients usually reach the healthcare system with hypertension, atrial fibrillation, coronary disease, or fatigue — not with a complaint that they stop breathing at night.

Reason	Why it hides the disease
The patient is asleep	The events and arousals happen below conscious awareness and are not remembered
Symptoms are nonspecific	Fatigue and poor concentration get attributed to age, stress, or overwork
No bed partner	Often no one is present to witness the snoring, gasping, or silent pauses
Sleepiness is not universal	Severe disease can feel mild, so the absence of sleepiness falsely reassures
Attention is on downstream disease	Hypertension, AF, or coronary disease is diagnosed and treated while the OSA driving it goes unexamined

How Obstructive Sleep Apnea Damages the Cardiovascular System

OSA injures the cardiovascular system through four mechanisms that interlock, and together they explain why its reach extends across so much of cardiovascular medicine.

Intermittent Hypoxia

Each apnea drops oxygen, but the damage comes less from low oxygen than from the cycling — oxygen falls, returns, falls again.(4) That pattern is uniquely destructive. When blood flow returns to oxygen-starved tissue, the reoxygenation itself injures cells: reactive oxygen species generated by the swing from low to normal oxygen damage tissue and switch on inflammatory pathways. This is ischemia-reperfusion injury, a major mechanism of harm after a heart attack.(5)

OSA delivers that injury on a smaller scale but relentlessly — potentially dozens of times an hour, hundreds of times a night, for years. The main target is the vascular endothelium, the single-cell lining of every blood vessel that controls vascular tone, clotting, and inflammation.(6, 7) The result is elevated inflammatory markers, impaired endothelial function, and insulin resistance — a vascular environment that breeds atherosclerosis.(8) It is the same kind of ischemia-reperfusion injury that harms heart muscle after an infarction, delivered here to the vasculature systemically, every night, for years.

Intrathoracic Pressure Swings

When the airway is shut and the diaphragm keeps pulling, the chest generates extreme negative pressure — well beyond anything normal breathing produces — and that stresses the heart mechanically.(9) The negative pressure raises the gradient the left ventricle pumps against, increasing afterload, and it pulls venous blood into the thorax, increasing right-heart filling. Combined with hypoxic constriction of the pulmonary vessels, it strains both ventricles.(10, 11)

Night after night, this mechanical load contributes to left ventricular hypertrophy, right-heart strain, and pulmonary hypertension. The repeated stretch of the atria from the pressure swings and shifting blood volume also helps set the stage for atrial fibrillation.(12)

Sympathetic Nervous System Activation

Each arousal that ends an apnea fires a sympathetic surge — heart rate up, blood pressure up, vessels constricted.(13, 14) The activation does not stay confined to sleep. People with OSA carry elevated sympathetic tone even while awake; their baseline is shifted up, and the normal 10–20% nocturnal blood-pressure dip is often blunted or reversed, leaving daytime pressure high.(15)

This sustained activation is why OSA is recognized as one of the most common identifiable causes of resistant hypertension — pressure that stays high despite multiple medications.(16) The same mix of sympathetic surges, hypoxia, and electrolyte shifts also creates conditions that favor arrhythmia: atrial fibrillation, ventricular ectopy, and bradyarrhythmias have all been linked to OSA.(17)

Sleep Fragmentation

The repeated arousals fragment sleep architecture and block the sustained NREM sleep that cardiovascular recovery depends on, described in Article 1.(18) Even when time in bed looks adequate, the constant interruptions prevent the deep sleep during which blood pressure is lowest and the parasympathetic system dominates. The metabolic, inflammatory, and vascular consequences resemble those of the chronic sleep restriction covered in Article 2.

The Mechanisms Reinforce One Another

These four do not act alone. Intermittent hypoxia drives inflammation and oxidative stress, which impair the endothelium and accelerate atherosclerosis; stiffer, narrower arteries raise blood pressure and cardiac workload; the pressure swings and sympathetic surges pile mechanical and neural stress on top; and the fragmentation removes the recovery that might otherwise offset some of it.(19) Each night the loop runs again and the damage compounds. That convergence is why OSA is associated with the whole spectrum of cardiovascular disease rather than any single condition.

The chain, in brief:

OSA mechanism	Cardiovascular result
Intermittent hypoxia	Oxidative stress, inflammation, endothelial injury
Sympathetic surges	Higher blood pressure; arrhythmia risk
Intrathoracic pressure swings	Mechanical strain on both ventricles; atrial stretch
Sleep fragmentation	Loss of the nightly cardiovascular recovery period
All four combined, nightly	Atherosclerosis, hypertension, atrial fibrillation, heart failure, stroke

Obstructive Sleep Apnea and Specific Cardiovascular Conditions

Hypertension

OSA is one of the most important identifiable causes of hypertension, and it is especially common in resistant hypertension — pressure that stays above goal despite three or more drugs including a diuretic.(16) Studies of resistant hypertension consistently find a high prevalence, commonly above 60% and exceeding 80% in some series.(16, 21) The Wisconsin Sleep Cohort showed a dose-response relationship: more severe OSA predicted greater risk of developing hypertension over four years, independent of obesity.(20)

The mechanism is the one above — repeated sympathetic surges, loss of nocturnal dipping, and a daytime sympathetic tone that never resets. The cardiovascular system never gets the sustained low-pressure window that should define sleep. The practical implication is that guidelines suggest considering an OSA evaluation in resistant hypertension, and when OSA is found and effectively treated, blood pressure can improve — though the average reduction is modest, and it is largest in patients with resistant hypertension.(35)

Atrial Fibrillation

OSA is present in roughly 40–50% of patients with atrial fibrillation, but the relationship runs past prevalence into treatment outcomes.(22) Untreated OSA is associated with AF recurrence after both cardioversion and ablation — the procedure works, then the rhythm returns, plausibly because the nightly stress on the atria continues.(23) Atrial stretch from the pressure swings, hypoxia-driven electrical instability, autonomic dysfunction, chronic remodeling, and systemic inflammation all likely contribute.(12)

In practice, this is why AF that is hard to control or that returns after treatment often prompts an OSA evaluation. Much of this evidence is observational, and randomized proof that treating OSA prevents AF is still limited, but treating it may be necessary for rhythm control to hold in some patients.(12) The broader cardiometabolic links between AF and sleep are taken up in Article 8.

Coronary Artery Disease

Studies of patients referred for coronary bypass have found OSA in 70–87%, much of it moderate-to-severe and most of it undiagnosed before the cardiac workup.(45, 46) These patients did not arrive with sleep complaints — they came with angina, abnormal stress tests, and coronary disease. The OSA was found incidentally, even though it may have been contributing for years through endothelial dysfunction, inflammation, oxidative stress, and repeated pressure surges. Beyond promoting plaque formation, that inflammatory, oxidative environment may also contribute to plaque instability — the vulnerability that precedes rupture — though this link remains mechanistic and is not yet shown to change outcomes. Prospective data link OSA to incident coronary heart disease and heart failure as well.(24)

The acute problem is a supply-demand mismatch: during each apnea myocardial oxygen demand rises as sympathetic activation drives up heart rate and pressure, while supply falls with desaturation. For a heart already narrowed by coronary disease, that is the setup for ischemia — during sleep, when the patient expects to be at rest. Over the long run, severe sleep-disordered breathing has been associated with roughly threefold higher all-cause mortality across eighteen years in the Wisconsin cohort.(25)

Heart Failure

The relationship with heart failure runs both ways.(26) On one side, the chronic hypertension OSA produces drives left ventricular hypertrophy and dysfunction, the pressure swings strain both ventricles, intermittent hypoxia impairs myocardial function, and the neurohormonal activation mirrors heart failure’s own. On the other, heart failure worsens OSA: lying down redistributes fluid from the legs to the upper body, increasing airway edema and collapsibility, while reduced cardiac output destabilizes respiratory control. Central events often develop alongside the obstructive ones.

Sleep-disordered breathing — obstructive, central, or mixed — is highly prevalent in heart failure patients, though estimates vary with heart-failure type and severity, and prospective data tie OSA to incident heart failure.(24, 26) Many patients are caught in a loop where each condition worsens the other. Treatment in this setting is more complex and carries safety considerations specific to heart failure, which Article 4 addresses directly.

Stroke

OSA raises stroke risk through several routes: hypertension, atrial fibrillation and its embolic strokes, cerebral atherosclerosis, and possibly impaired cerebral autoregulation during hypoxic episodes.(27)

The relationship is bidirectional. Sleep-disordered breathing is strikingly common after stroke: a meta-analysis found it in up to roughly 70% of stroke and TIA patients, the great majority obstructive.(49) It is even more frequent after recurrent strokes than after first events. It is associated with worse functional recovery and higher recurrence risk, and because clinical history alone misses many cases, testing is reasonable to consider after a stroke or TIA. Where OSA and atrial fibrillation coexist, their stroke risks compound, since each promotes the other.

Sudden Cardiac Death

In the general population, sudden cardiac death follows a circadian pattern — lowest during sleep, peaking in the morning — because sleep is normally protective, with parasympathetic dominance, lower pressure, and reduced workload. In severe OSA that pattern appears to invert: among people who died suddenly during the sleeping hours of midnight to 6 a.m., OSA was significantly associated with death in that window, a time when sudden death is otherwise uncommon.(28) It is a clean illustration of the article’s theme — sleep, which should protect the heart, turned into a period of repeated stress.

The Cardiometabolic Connection

The same mechanisms feed metabolism, not only the heart and vessels directly. Intermittent hypoxia and the repeated sympathetic surges promote insulin resistance, and OSA is independently associated with the cluster that defines metabolic syndrome — central obesity, high blood pressure, an adverse lipid pattern, and rising glucose.(8, 19) That places OSA upstream of type 2 diabetes and atherosclerosis as well, which is part of why it rarely travels alone. The broader cardiometabolic picture, and how these threads converge, is the subject of Article 8.

Who Should Be Evaluated

Given the cardiovascular stakes and the volume of undiagnosed disease in cardiac populations, knowing who warrants testing matters.

Risk Factors and Symptoms

The classic risk factors are summarized below; obesity is the strongest of them, though it is not the whole story.

Risk factor	Detail
Obesity	Strongest modifiable risk factor; in the Wisconsin cohort a 10% weight gain was associated with roughly sixfold higher odds of developing moderate-to-severe OSA(29)
Male sex	Higher prevalence in men; the gap narrows after menopause(1)
Age	Prevalence rises with age, with some plateau in older groups(1)
Craniofacial anatomy	Receding jaw, large tonsils, nasal obstruction, a crowded airway(2)
Family history	A heritable component tied to craniofacial structure and fat distribution(30)

The symptoms are easy to dismiss. Loud snoring — especially with witnessed pauses or gasping — is the most specific. Others include excessive daytime sleepiness, unrefreshing sleep despite adequate time in bed, morning headaches that resolve within hours of waking, and nocturia. One caution carries real weight: cardiovascular risk from OSA can be present even in people who do not feel particularly sleepy, so the absence of sleepiness does not rule out clinically significant disease. Presentation can also vary by sex — women more often describe fatigue, insomnia, or low mood than the classic loud snoring and witnessed pauses. Partly for that reason, OSA in women is often recognized later, its symptoms attributed instead to insomnia, depression, stress, or menopause rather than to sleep-disordered breathing.

It is worth being precise about obesity, since it is the most common misconception about OSA. Obesity raises risk through real mechanisms: fat around the neck and tongue narrows the airway, and abdominal fat lowers lung volume, which loosens the airway’s tethering during sleep.(2) But anatomy can produce OSA on its own — a set-back jaw, a large tongue, or a crowded airway can cause significant disease in someone who is lean. That is why thin people get OSA too, and why weight is a major risk factor rather than a prerequisite.

Cardiovascular Conditions That Often Prompt Evaluation

Because the prevalence is so high and the relationships bidirectional, several cardiac conditions justify looking for OSA even without classic symptoms: resistant hypertension (highly prevalent), atrial fibrillation (particularly when rhythm control is difficult or AF recurs after treatment), heart failure, coronary artery disease (especially severe disease), stroke or TIA, and pulmonary hypertension. Undiagnosed OSA also matters around surgery: in patients undergoing cardiac and other major operations, unrecognized OSA is associated with more postoperative complications, which is part of why anesthesiologists screen for it before an operation.(46) In some patients OSA first comes to light only around surgery, when unexplained postoperative oxygen desaturations or complications prompt the sleep evaluation that finally identifies it.

Screening Questionnaires

Two tools help decide who needs a sleep study. The most widely used is STOP-Bang, an eight-item yes/no checklist whose name spells out the items. Each “yes” scores one point, for a total of 0 to 8.(31) Every item is a recognized marker of OSA, which is why a higher score raises the probability of disease.

Item	What it asks	Why it points to OSA
S — Snoring	Loud habitual snoring — loud enough to be heard through a closed door or to disturb a bed partner	Snoring is the sound of turbulent airflow through a narrowed, vibrating pharynx — the same collapsibility that produces apneas
T — Tiredness	Daytime tiredness, fatigue, or dozing off	Reflects the fragmented, non-restorative sleep caused by repeated overnight arousals
O — Observed apneas	Has anyone seen you stop breathing, choke, or gasp during sleep	The most specific symptom — a witnessed pause is a direct observation of the obstruction itself
P — Pressure	High blood pressure, or treatment for it	OSA is a leading contributor to hypertension, especially the resistant form, so elevated pressure raises pretest probability
B — BMI	Body mass index over 35 kg/m²	Excess weight adds fat around the pharynx and lowers lung volume, both of which make the airway more collapsible
A — Age	Older than 50 years	Airway dilator-muscle tone and soft-tissue properties change with age, and prevalence rises accordingly
N — Neck	Neck circumference over 40 cm	A thick neck marks fat deposited around the airway, narrowing the space available for airflow
G — Gender	Male	Men carry a substantially higher prevalence; in women the risk rises after menopause

Scores are read in bands: 0 to 2 is low risk for moderate-to-severe OSA, 3 to 4 is intermediate, and 5 to 8 is high.(47) The checklist is deliberately tuned to catch as many cases as possible, so it is sensitive but not specific. A score of 3 or more detects roughly 93% of moderate-to-severe OSA and nearly all severe cases, but at the cost of many false positives.(47) A low score therefore helps rule the disease out, while a high score flags someone for testing rather than confirming it.

The Epworth Sleepiness Scale takes a different angle. It asks how likely the person is to doze in eight ordinary, low-stimulation situations, with responses summing to a score from 0 to 24.(32) Higher totals suggest excessive daytime sleepiness that warrants evaluation. Neither tool diagnoses OSA — they only flag who should be tested, and the diagnosis still rests on the sleep study.

Diagnosis

Diagnosis requires objective measurement of breathing during sleep.

In-laboratory polysomnography is the reference standard.(33) Performed overnight with a technician present, it records brain waves, eye movements, muscle tone, airflow, respiratory effort, oxygen saturation, heart rhythm, body position, and leg movements. It gives the most complete picture, stages sleep accurately, can detect other sleep disorders, and allows split-night studies that diagnose in the first half and titrate CPAP in the second. Its drawbacks are an unfamiliar environment that can distort sleep, higher cost and lower access, and a “first-night effect” that may not represent a typical night.

Home sleep apnea testing uses a portable device in the patient’s own bed.(34) It typically records airflow, respiratory effort, oxygen saturation, and heart rate, but not brain waves — so it cannot stage sleep or confirm actual sleep time. It is cheaper, more accessible, and may better reflect a normal night. But it cannot identify other sleep disorders, it tends to underestimate severity because it uses total recording time rather than actual sleep time as the denominator, and it has a higher technical-failure rate. It is not appropriate for everyone.

The choice between them depends on the clinical picture.

Scenario	Typical approach
High probability of moderate-severe OSA, no significant comorbidities	Home testing often appropriate
Significant cardiopulmonary disease (heart failure, severe COPD)	Laboratory polysomnography often preferred
Suspected central sleep apnea or hypoventilation	Laboratory polysomnography
Suspected coexisting sleep disorders	Laboratory polysomnography
Negative home test despite high clinical suspicion	Laboratory polysomnography

One caveat applies to any single study: OSA severity is not fixed from night to night. Alcohol, sleeping position, nasal congestion, sleep deprivation, and how much REM sleep occurs can all shift the number of events, so one night is a sample rather than a fixed value. A study done on an atypical night — little REM, or mostly side-sleeping in someone whose disease is supine-predominant — can understate the usual burden.

Interpreting the AHI

The apnea-hypopnea index counts apneas plus hypopneas per hour of sleep, and it defines severity.(33)

AHI (events/hour)	Severity
Under 5	Normal
5–14	Mild
15–29	Moderate
30 or more	Severe

The AHI is important but incomplete. Two people with the same index can have very different disease. One may have events confined to REM sleep and the supine position with mild dips to 88%; the other may have events in every stage and position with desaturations to 65%. Same AHI, very different oxygen exposure, and likely very different cardiovascular risk. The index counts events but says nothing about the oxygen nadir, the total time spent in hypoxia, the intensity of arousals, or the symptom burden. The pattern matters, not just the number.

REM sleep deserves a specific mention. Because muscle tone falls to its lowest during REM, the airway is most collapsible then, and REM events tend to last longer and drop oxygen further. Some people carry a near-normal overall AHI but severe, heavily desaturating disease concentrated in REM — easy to underrate if REM was short during the study. Given REM’s distinct cardiovascular profile, described in Article 1, REM-predominant disease is worth flagging rather than averaging away.

This is why the field is increasingly looking past the AHI to measures that capture how much hypoxic stress the body actually absorbs. The leading example is the hypoxic burden — the total depth and duration of the oxygen dips an apnea causes, not merely how often they occur. In large cohort studies it predicted cardiovascular mortality more strongly than the AHI did, which fits the clinical reality that two people with identical indices can carry very different risk.(48) Oxygen burden, the cumulative time spent below a saturation threshold, captures a related idea. None of these has replaced the AHI in routine practice, but they explain why the index alone can understate the disease — and why the oxygen tracing, not just the event count, deserves attention.

Treatment

CPAP, the First-Line Treatment

Continuous positive airway pressure delivers pressurized air through a mask that splints the airway open and prevents collapse.(35) When it is effective and used consistently, it eliminates obstructive events and the desaturations that follow, abolishes the intrathoracic pressure swings, restores sleep continuity, and lowers sympathetic activation. Some of these effects appear from the first night of effective use.

Timeframe	Documented effects
Immediate	Elimination of apneas and hypopneas; prevention of desaturation; improved sleep continuity
Days to weeks	Blood-pressure reduction; less daytime sleepiness; improved cognition
Months	Sustained blood-pressure improvement; reduced sympathetic tone; improved endothelial function; lower inflammatory markers

The catch is adherence. CPAP works only when it is worn, and many patients find masks uncomfortable, develop nasal dryness, feel claustrophobic, or do not perceive enough benefit to justify the bother.(36) The benefit appears dose-dependent — more hours per night generally means more benefit, with trials often using a four-hour threshold even though more is likely better. Most early problems are solvable, which is why troubleshooting before abandonment is worthwhile: proper mask fitting across several mask types, heated humidification, treating nasal congestion, gradual acclimatization, regular follow-up, and modern comfort features such as pressure ramping and auto-adjusting pressure. Many who ultimately succeed with CPAP describe the first few weeks as the hardest stretch — adaptation, not failure — which is exactly why early support and follow-up matter.

Alternative Treatments

When CPAP is not tolerated or not the right fit, several alternatives exist, each with its own indications and limits.

Treatment	Appropriate for	Limitations
Auto-adjusting PAP (APAP)	Most patients with uncomplicated OSA	Similar to CPAP; may be more comfortable for some(37)
Oral appliances	Mild-to-moderate OSA; CPAP intolerance	Less effective for severe disease; needs a trained dental provider(38)
Positional therapy	Position-dependent OSA (events mainly supine)	Only effective when disease is truly position-dependent(39)
Hypoglossal nerve stimulation	Moderate-severe OSA; CPAP failure; specific criteria	Surgical implant; careful patient selection required(40)
Upper-airway surgery	Specific anatomic abnormalities; CPAP failure	Variable outcomes; reserved for selected cases(41)
Weight loss	Patients with obesity and OSA	Meaningful benefit — about a 26% AHI reduction with 10% weight loss — but it should accompany, not replace, primary treatment(29)

A word specifically on weight loss: even substantial loss usually improves OSA more than it eliminates it, because where airway anatomy is also driving the collapse, shedding fat cannot fully reopen the airway. That is why it belongs alongside primary treatment rather than in place of it.

What the Clinical Trials Show — and Don’t

Any discussion of OSA and cardiovascular disease has to address the SAVE trial, which is cited often and misread often.(42)

SAVE randomized 2,717 adults who had moderate-to-severe OSA plus established cardiovascular or cerebrovascular disease to CPAP plus usual care or to usual care alone. The primary outcome was a composite of cardiovascular events over a mean 3.7 years. The result was no significant difference in cardiovascular events between groups; CPAP improved snoring, sleepiness, quality of life, and mood, but not the primary cardiac endpoint.

SAVE is often summarized as “CPAP doesn’t prevent cardiovascular disease,” and that reading is too broad.(43) What the trial actually answered is narrow: does CPAP, at the adherence achieved here — an average of 3.3 hours a night — reduce cardiovascular events in people who already have established disease, over 3.7 years? The answer was no detectable difference. What it did not answer is whether CPAP at higher adherence (six or more hours) reduces events, whether treating OSA before cardiovascular disease develops prevents that disease, whether longer than 3.7 years would show benefit, or whether other treatments affect outcomes.

The context matters. The SAVE population carried decades of accumulated vascular damage, and average use was only 3.3 hours a night, below typical adherence thresholds. Expecting modest treatment of late-stage disease to reverse decades of damage in under four years may not have been the right hypothesis.(43, 44) This distinction runs throughout medicine: reversing an established disease after decades of exposure is a different task from preventing that exposure in the first place. The mechanisms linking OSA to cardiovascular harm remain well established, and SAVE does not overturn them. It shows we have not proven that modest CPAP adherence reverses established disease in the short term — a gap in evidence, not proof that treatment does not help. Treatment still makes clear sense for symptoms, for blood pressure (which CPAP lowers, particularly in resistant hypertension), and plausibly for cardiovascular protection with good adherence, earlier intervention, or specific populations. What is missing is the definitive randomized trial showing event reduction.

What This Means for Your Cardiovascular Health

If you have resistant hypertension, OSA is present in the majority of patients in your situation. When pressure stays uncontrolled despite multiple drugs, an evaluation may find a treatable contributor, and effective treatment can improve control — sometimes reducing the medication burden.

If you have atrial fibrillation, OSA is common and associated with treatment failure. If AF recurs after cardioversion or ablation, or if rhythm control is difficult, untreated OSA may be part of the reason, and evaluation may be relevant to managing the rhythm.

If you have coronary artery disease, OSA is common and mostly undiagnosed — the majority of bypass patients in the studied cohorts have it. The nightly desaturations and pressure surges create a supply-demand mismatch for the heart, so evaluation is worth considering, especially with unexplained symptoms or disease progression.

If you have heart failure, sleep-disordered breathing — obstructive, central, or both — is highly prevalent, and the conditions worsen each other. Evaluation is often warranted, though treatment here is more complex than in the general population and carries heart-failure-specific safety considerations, taken up in Article 4.

If you snore heavily or have witnessed apneas, these are the most specific signs of OSA. Evaluation is straightforward and can identify a treatable condition with real cardiovascular implications.

If you are sleepy despite adequate sleep time, that can mean fragmented sleep from OSA or another disorder, and testing can identify the cause.

Common Assumptions Measured Against the Physiology

Common assumption	What the evidence shows
“OSA is a sleep problem, not a heart problem.”	Its breathing events drive hypertension, atrial fibrillation, and atherosclerosis; the most consequential effects are cardiovascular.
“If I’m not sleepy, I don’t have it.”	Cardiovascular risk can be present with little daytime sleepiness; the absence of sleepiness does not rule out significant disease.
“Only people who are overweight get OSA.”	Obesity is the strongest risk factor but is not required; craniofacial anatomy alone can cause it.
“Snoring is harmless.”	Loud snoring with witnessed pauses or gasping is one of the most specific signs of OSA.
“SAVE proved CPAP doesn’t help the heart.”	SAVE tested low adherence in established disease and found no event reduction; it did not prove treatment is useless, and blood pressure and symptoms still improve.

The Bottom Line

Obstructive sleep apnea is a condition in which the airway repeatedly collapses during sleep, producing oxygen desaturation, extreme intrathoracic pressure swings, sympathetic surges, and sleep fragmentation — dozens of times an hour in moderate-to-severe disease. It turns sleep, the cardiovascular system’s recovery shift, into a series of small stress tests the person never feels. The mechanisms are direct and reinforce each other: intermittent hypoxia delivers oxidative stress to the endothelium, pressure swings strain the heart, sympathetic activation raises blood pressure and promotes arrhythmia, and fragmentation blocks recovery — together driving hypertension, coronary disease, atrial fibrillation, heart failure, and stroke. Few risk factors do so much at once, and almost none do it so invisibly: OSA works entirely while the person is unconscious, so there is no symptom to act on, and it is usually a bed partner or a puzzled clinician who notices first. CPAP eliminates obstructive events when used consistently and improves blood pressure and symptoms, but adherence is hard, and the SAVE trial did not show event reduction with modest adherence in established disease — so treatment is clearly warranted for symptoms and blood pressure, while event prevention remains biologically sound but unproven by trial. For anyone with resistant hypertension, recurrent atrial fibrillation, heart failure, or coronary disease, the prevalence is too high to ignore, and looking for it is often the highest-yield step left.

What Comes Next

Article 4 turns to central sleep apnea and sleep-disordered breathing in heart failure — a different mechanism, where the airway stays open and the brain briefly stops sending the signal to breathe. It carries different treatment implications, and one important safety lesson, for people with established cardiac disease.

Key Terms

Obstructive sleep apnea (OSA): Repeated episodes of upper-airway collapse during sleep, causing apneas (complete obstruction) or hypopneas (partial obstruction) with oxygen desaturation and sleep fragmentation.

Apnea: Cessation of airflow for at least 10 seconds. In obstructive apnea, respiratory effort continues against a closed airway; in central apnea, effort is absent.

Hypopnea: Reduction in airflow (typically 30% or more) for at least 10 seconds, with oxygen desaturation or arousal.

Apnea-hypopnea index (AHI): Apneas plus hypopneas per hour of sleep. Severity: under 5 normal; 5–14 mild; 15–29 moderate; 30 or more severe.

Intermittent hypoxia: The repeated cycles of oxygen desaturation and reoxygenation characteristic of OSA, producing oxidative stress, inflammation, and endothelial dysfunction.

CPAP (continuous positive airway pressure): First-line treatment that delivers pressurized air through a mask to splint the upper airway open.

Resistant hypertension: Blood pressure above goal despite three or more antihypertensive medications at adequate doses, including a diuretic. OSA is one of the most common identifiable causes.

Nocturnal dipping: The normal 10–20% fall in blood pressure during sleep relative to daytime values. OSA often blunts or reverses it.

References

1. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-1014. doi:10.1093/aje/kws342. PMID: 23589584.
2. Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008;5(2):144-153. doi:10.1513/pats.200707-114MG. PMID: 18250206.
3. Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47-112. doi:10.1152/physrev.00043.2008. PMID: 20086074.
4. Lévy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers. 2015;1:15015. doi:10.1038/nrdp.2015.15. PMID: 27188535.
5. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia — revisited — the bad ugly and good: implications to the heart and brain. Sleep Med Rev. 2015;20:27-45. doi:10.1016/j.smrv.2014.07.003. PMID: 25155182.
6. Arnaud C, Dematteis M, Pepin JL, Baguet JP, Lévy P. Obstructive sleep apnea, immuno-inflammation, and atherosclerosis. Semin Immunopathol. 2009;31(1):113-125. doi:10.1007/s00281-009-0148-5. PMID: 19404644.
7. Ip MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med. 2004;169(3):348-353. doi:10.1164/rccm.200306-767OC. PMID: 14551167.
8. Punjabi NM, Beamer BA. Alterations in glucose disposal in sleep-disordered breathing. Am J Respir Crit Care Med. 2009;179(3):235-240. doi:10.1164/rccm.200809-1392OC. PMID: 19011148.
9. Shiomi T, Guilleminault C, Stoohs R, Schnittger I. Leftward shift of the interventricular septum and pulsus paradoxus in obstructive sleep apnea syndrome. Chest. 1991;100(4):894-902. doi:10.1378/chest.100.4.894. PMID: 1914603.
10. Buda AJ, Pinsky MR, Ingels NB Jr, Daughters GT 2nd, Stinson EB, Alderman EL. Effect of intrathoracic pressure on left ventricular performance. N Engl J Med. 1979;301(9):453-459. doi:10.1056/NEJM197908303010901. PMID: 460363.
11. Sajkov D, Wang T, Saunders NA, Bune AJ, McEvoy RD. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2002;165(2):152-158. doi:10.1164/ajrccm.165.2.2010092. PMID: 11790646.
12. Linz D, McEvoy RD, Cowie MR, et al. Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review. JAMA Cardiol. 2018;3(6):532-540. doi:10.1001/jamacardio.2018.0095. PMID: 29541763.
13. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96(4):1897-1904. doi:10.1172/JCI118235. PMID: 7560081.
14. Tilkian AG, Guilleminault C, Schroeder JS, Lehrman KL, Simmons FB, Dement WC. Hemodynamics in sleep-induced apnea: studies during wakefulness and sleep. Ann Intern Med. 1976;85(6):714-719. doi:10.7326/0003-4819-85-6-714. PMID: 999107.
15. Wolf J, Hering D, Narkiewicz K. Non-dipping pattern of hypertension and obstructive sleep apnea syndrome. Hypertens Res. 2010;33(9):867-871. doi:10.1038/hr.2010.153. PMID: 20818398.
16. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-817. doi:10.1161/HYPERTENSIONAHA.111.179788. PMID: 21968750.
17. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. Am J Respir Crit Care Med. 2006;173(8):910-916. doi:10.1164/rccm.200509-1442OC. PMID: 16424443.
18. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest. 2010;137(1):95-101. doi:10.1378/chest.09-0791. PMID: 19542260.
19. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013;62(7):569-576. doi:10.1016/j.jacc.2013.05.045. PMID: 23770180.
20. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342(19):1378-1384. doi:10.1056/NEJM200005113421901. PMID: 10805822.
21. Muxfeldt ES, Margallo VS, Guimarães GM, Salles GF. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. Am J Hypertens. 2014;27(8):1069-1078. doi:10.1093/ajh/hpu023. PMID: 24705438.
22. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110(4):364-367. doi:10.1161/01.CIR.0000136587.68725.8E. PMID: 15249509.
23. Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003;107(20):2589-2594. doi:10.1161/01.CIR.0000068337.25994.21. PMID: 12743002.
24. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation. 2010;122(4):352-360. doi:10.1161/CIRCULATIONAHA.109.901801. PMID: 20625114.
25. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31(8):1071-1078. doi:10.5665/sleep/31.8.1071. PMID: 18714778.
26. Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841-858. doi:10.1016/j.jacc.2016.11.069. PMID: 28209226.
27. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353(19):2034-2041. doi:10.1056/NEJMoa043104. PMID: 16282178.
28. Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med. 2005;352(12):1206-1214. doi:10.1056/NEJMoa041832. PMID: 15788497.
29. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-3021. doi:10.1001/jama.284.23.3015. PMID: 11122588.
30. Redline S, Tishler PV, Tosteson TD, et al. The familial aggregation of obstructive sleep apnea. Am J Respir Crit Care Med. 1995;151(3 Pt 1):682-687. doi:10.1164/ajrccm/151.3_Pt_1.682. PMID: 7881656.
31. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008;108(5):812-821. doi:10.1097/ALN.0b013e31816d83e4. PMID: 18431116.
32. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545. doi:10.1093/sleep/14.6.540. PMID: 1798888.
33. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479-504. doi:10.5664/jcsm.6506. PMID: 28162150.
34. Rosen CL, Auckley D, Benca R, et al. A multisite randomized trial of portable sleep studies and positive airway pressure autotitration versus laboratory-based polysomnography for the diagnosis and treatment of obstructive sleep apnea: the HomePAP study. Sleep. 2012;35(6):757-767. doi:10.5665/sleep.1870. PMID: 22654195.
35. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2019;15(2):301-334. doi:10.5664/jcsm.7638. PMID: 30736888.
36. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008;5(2):173-178. doi:10.1513/pats.200708-119MG. PMID: 18250209.
37. Ip S, D’Ambrosio C, Patel K, et al. Auto-titrating versus fixed continuous positive airway pressure for the treatment of obstructive sleep apnea: a systematic review with meta-analyses. Syst Rev. 2012;1:20. doi:10.1186/2046-4053-1-20. PMID: 22587875.
38. Ramar K, Dort LC, Katz SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J Clin Sleep Med. 2015;11(7):773-827. doi:10.5664/jcsm.4858. PMID: 26094920.
39. Ravesloot MJ, van Maanen JP, Dun L, de Vries N. The undervalued potential of positional therapy in position-dependent snoring and obstructive sleep apnea — a review of the literature. Sleep Breath. 2013;17(1):39-49. doi:10.1007/s11325-012-0683-5. PMID: 22441662.
40. Strollo PJ Jr, Soose RJ, Maurer JT, et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014;370(2):139-149. doi:10.1056/NEJMoa1308659. PMID: 24401051.
41. Aurora RN, Casey KR, Kristo D, et al. Practice parameters for the surgical modifications of the upper airway for obstructive sleep apnea in adults. Sleep. 2010;33(10):1408-1413. doi:10.1093/sleep/33.10.1408. PMID: 21061864.
42. McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375(10):919-931. doi:10.1056/NEJMoa1606599. PMID: 27571048.
43. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S; INCOSACT Initiative. Sleep apnea and cardiovascular disease: lessons from recent trials and need for team science. Circulation. 2017;136(19):1840-1850. doi:10.1161/CIRCULATIONAHA.117.029400. PMID: 29109195.
44. Javaheri S, Martinez-Garcia MA, Campos-Rodriguez F, Muriel A, Peker Y. Continuous positive airway pressure adherence for prevention of major adverse cerebrovascular and cardiovascular events in obstructive sleep apnea. Am J Respir Crit Care Med. 2020;201(5):607-610. doi:10.1164/rccm.201908-1593LE.
45. Danzi-Soares NJ, Genta PR, Nerbass FB, et al. Obstructive sleep apnea is common among patients referred for coronary artery bypass grafting and can be diagnosed by portable monitoring. Coron Artery Dis. 2012;23(1):31-38. doi:10.1097/MCA.0b013e32834df5d0. PMID: 22107804.
46. Foldvary-Schaefer N, Kaw R, Collop N, et al. Prevalence of undetected sleep apnea in patients undergoing cardiovascular surgery and impact on postoperative outcomes. J Clin Sleep Med. 2015;11(10):1083-1089. doi:10.5664/jcsm.5076. PMID: 26094932.
47. Chung F, Abdullah HR, Liao P. STOP-Bang questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149(3):631-638. doi:10.1378/chest.15-0903. PMID: 26378880.
48. Azarbarzin A, Sands SA, Stone KL, et al. The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Eur Heart J. 2019;40(14):1149-1157. doi:10.1093/eurheartj/ehy624. PMID: 30376054.
49. Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med. 2010;6(2):131-137. doi:10.5664/jcsm.27760. PMID: 20411688.

HeartBuddi • Your heart. Own it.